News

FTD is a rare and rapidly progressing neurodegenerative disease caused by multiple hereditary factors, including mutations in the progranulin (GRN)…

Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that…

Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its…

Combining expertise to advance precision medicine, while enabling efficient and timely insights into the diagnosis of rare diseases and hereditary…

Working together to deliver data-driven, informative genotyping answers to accelerate and de-risk drug discovery, development, and commercialization…

Leveraging Rare Disease Insights Powered by the CENTOGENE Biodatabank and Centralized Multiomic Laboratories in Clinical Trials

CENTOGENE has received notification from the Nasdaq Stock Market LLC Listing Qualifications Department that it was not in compliance with the minimum…

The Company’s Pharma and CRO business development team and Diagnostics sales team will be attending events in the U.S. and Japan. CENTOGENE invites…